Ni Jing, Nolte Britta, Arnold Annette, Fournier Philippe, Schirrmacher Volker
Division of Cellular Immunology, German Cancer Research Center (DKFZ), Tumor Immunology Program, D-69120 Heidelberg, Germany.
Vaccine. 2009 Sep 4;27(40):5480-7. doi: 10.1016/j.vaccine.2009.07.001. Epub 2009 Jul 17.
We describe for the first time a short sequence of the CD11c promoter (700 bp, named as CD11cS) which induces selective antigen expression in dendritic cells (DCs). It showed a stronger promoter activity than the hitherto used long CD11c promoter (5.5 kb, named as CD11cL), which had been reported inefficient to induce immune responses. After application to the ear pinna and electroporation (EP), CD11cS based DNA vaccines induced specific B- and T-cell responses, including IFN-gamma secretion. Such vaccines achieved induction of anti-tumor immunity comparable in strength to vaccines having the strong tissue non-specific CMV promoter, in both prophylactic and therapeutic settings of mouse tumor models. This short CD11c promoter appears to be a safe and a practical tool for DC-specific gene targeting and for vaccination.
我们首次描述了一段CD11c启动子的短序列（700碱基对，命名为CD11cS），它能在树突状细胞（DC）中诱导选择性抗原表达。它表现出比迄今使用的长CD11c启动子（5.5千碱基对，命名为CD11cL）更强的启动子活性，据报道后者诱导免疫反应的效率较低。将基于CD11cS的DNA疫苗应用于耳廓并进行电穿孔（EP）后，可诱导特异性B细胞和T细胞反应，包括γ干扰素分泌。在小鼠肿瘤模型的预防和治疗环境中，此类疫苗诱导的抗肿瘤免疫力强度与具有强组织非特异性巨细胞病毒启动子的疫苗相当。这种短的CD11c启动子似乎是用于DC特异性基因靶向和疫苗接种的安全实用工具。
